Navigation Links
Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
Date:11/3/2008

cts; our ability to transition our management teams effectively; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Critical Therapeutics' Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, as amended, filed with the SEC and other SEC filings, including, but not limited to, those set forth in the section entitled "Risks Related to Cornerstone" beginning on page 59 of the proxy statement/prospectus Critical Therapeutics filed with the SEC pursuant to Rule 424(b)(3) on October 6, 2008, and in other filings that Cornerstone Therapeutics makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We a
'/>"/>

SOURCE Cornerstone BioPharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
6. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
9. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
10. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
11. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... ... an automatic end to driving, says the August 2015 Harvard Health Letter. , ... to drive. It requires an individual assessment of skills," says Lissa Kapust, a ...
(Date:8/4/2015)... ... 2015 , ... Updated enrollment data on the top U.S. health plans, as ... at http://www.AISHealth.com . The data is free to all registered users to AISHealth.com. ... charts on the website’s “Data” section include:, , Top 25 ...
(Date:8/4/2015)... ... August 04, 2015 , ... The results of a three year clinical ... rare eye disease that progressively causes blindness, were published on June 23, 2015 in ... results of the trial, the implant, more commonly known as the “bionic eye,” is ...
(Date:8/4/2015)... Miramar Beach, FL (PRWEB) , ... August 04, 2015 , ... ... people are living with psoriatic disease and its uncomfortable symptoms such as dry, itching, ... suffer from psoriasis bounce from medication to medication before they find what’s right for ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... 20 finalists for America’s Favorite Veterinarian. The contest is put on by the ... committee from 500 nominees. Nominees were evaluated on community involvement, ethical behavior, passion ...
Breaking Medicine News(10 mins):Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3
... Increases 32% to $14.2 Million ... Sets Quarterly Record, MINNEAPOLIS, Feb. 25 ATS Medical, ... products and services, today reported financial results for the,fourth quarter ... was $14.2 million, up 32.4% from $10.7 million reported in ...
... exhalations hint at wide range of conditions , , ... that uses laser light to sample a person,s breath ... number of diseases, a U.S. study says. , This ... one day help doctors screen patients for diseases such ...
... drugs is a worry, study says, , , MONDAY, Feb. 25 ... advanced dementia are given antibiotics in the last two weeks ... is whether or not that therapy has any benefits, such ... And, of concern are the risks associated with antibiotic use, ...
... Capital Growth Planning Inc., form "MaxLife-CGP",Partners LLC., a California based ... to $100M dollars in face value, of which ... ... CALIFORNIA, Feb. 25 /PRNewswire-FirstCall/ - MaxLife Fund Corp.,(OTC:MXFD). MaxLife ...
... A sophisticated robotic dog could be a good companion ... living pet, a new Saint Louis University study suggests. ... homes interacted with Sparky, a living, medium-sized gentle mutt, ... that looks like a three-dimensional cartoon. , The most ...
... Metalsmith Michael Aram,will lend his support to another noteworthy ... doors to his flagship store on March,13th for a special ... New Delhi based charity that was,established in 1994, at a ... Foundation has committed itself to raising awareness on and,preventing the ...
Cached Medicine News:Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 2Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 3Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 4Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 5Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 6Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 7Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 8Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 9Health News:ATS Medical Announces Record Quarterly and Full Year Revenue 10Health News:Laser Screen Detects Diseases in Breath 2Health News:Antibiotic Use in Dementia Patients Questioned 2Health News:Antibiotic Use in Dementia Patients Questioned 3Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 2Health News:MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement 3Health News:Faux Fido eases loneliness in nursing home residents as well as real dog, SLU study finds 2
(Date:8/4/2015)... , Aug. 4, 2015 Among 1,000 U.S. ... yet only half of consumers surveyed are aware of ... ever used use them, according to findings from a ... community service partnership focused on improving the health and ... online survey polled 1,000 men and women, ages 21 ...
(Date:8/3/2015)... Aug. 4, 2015   The Intellectual Property ... world,s leading provider of intelligent information for businesses ... 2015 CMR Pharmaceutical R&D Factbook , the biopharmaceutical ... concerns around declines in R&D, the analysis identifies ... trillion milestone and forecasts sales to reach $1.3 ...
(Date:8/3/2015)... WARRINGTON, Pa. , Aug. 3, 2015 /PRNewswire/ ... a specialty biotechnology company focused on developing aerosolized ... a live teleconference and webcast at 8:30 a.m. Eastern ... time management will discuss the 2015 second quarter ... The company will issue a press release announcing ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Pharma Sales to Grow Beyond $1 Trillion 2Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2
... Perceptive Informatics, the industry,s leading eClinical solutions provider ... PRXL ), today announced the results ... entitled "Optimizing Adaptive Trial Designs: Using Simulation ... by Perceptive Informatics with partner Cytel Inc., a ...
... Pharmaceuticals announced today positive results from its clinical ... Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis.Prednisporin(TM) ... profile (no increase in intra-ocular pressure) than PredForte(TM), ... dose of prednisolone acetate, in patients treated for ...
Cached Medicine Technology:Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 2Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 3Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 4Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs 5Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 2Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis 3
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
BB Watchmaker Forceps, Pakistan, 4.5" fine point....
Penfield Watchmaker Forceps. Tip width 0.9 mm....
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
Medicine Products: